Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
NCT01998828 · Sierra Oncology LLC - a GSK company · PHASE2 · terminated · last registry update 2020-04-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Sierra Oncology LLC - a GSK company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-31Phase 3 first posted: University of Alabama at Birmingham, targeted synthetic DMARD class + non-TNFi-biologic class (NCT04692493)
- 2020-11-10Phase 3 first posted: Pfizer, tofacitinib (NCT04624230)
- 2020-10-26Phase 3 first posted: Novartis Pharmaceuticals, Pelabresib + Ruxolitinib (NCT04603495)
- 2020-09-24Phase 3 first posted: Karyopharm Therapeutics Inc, Selinexor + Selinexor (NCT04562389)
- 2020-07-15Phase 3 first posted: AbbVie, Placebo for Navitoclax + Ruxolitinib (NCT04472598)
- 2020-07-13Phase 3 first posted: AbbVie, Navitoclax + Ruxolitinib (NCT04468984)
- 2020-05-11Phase 3 first posted: University of Oxford, Lopinavir-Ritonavir + Corticosteroid (NCT04381936)
- 2019-11-19Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT04169373)
- 2019-11-13Phase 3 first posted: AbbVie, Upadacitinib + Placebo for Upadacitinib (NCT04161898)
- 2019-10-04Phase 3 first posted: University of Birmingham, Ruxolitinib + Hydroxycarbamide (NCT04116502)
- 2019-09-12Phase 3 first posted: Eli Lilly and Company, Baricitinib + Tocilizumab (NCT04088396)
- 2019-09-12Phase 3 first posted: Eli Lilly and Company, Baricitinib + Adalimumab (NCT04088409)
- 2019-05-16Phase 3 first posted: Eli Lilly and Company, Baricitinib + Placebo (NCT03952559)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision